Q1. Comparable foreign CRISPR-based gene therapies for Sickle Cell Disease, against which India's indigenously developed BIRSA 101 is being positioned as a low-cost alternative, are reported to be priced at approximately how many crore rupees per patient?
- A. Rs 5–10 crore
- B. Rs 20–25 crore
- C. Rs 50–60 crore
- D. Rs 100–120 crore